Pharming Reports on Financial Results for the First Half of 2017
Financial updatesPharming Group N.V. presents its (unaudited) financial report for the six months ended 30 June 2017.
Pharming Reports On Annual General Meeting Of Shareholders
Financial updatesPharming Group N.V. announces that at its Annual General Meeting of shareholders (AGM), held today, all proposals were approved.
Pharming announces withdrawal of agenda items related to Amendment of the Articles of Association from AGM agenda
Financial updatesPharming Group N.V. today announced that the supervisory board and the management board have jointly decided to withdraw the agenda items related to the Amendment of Pharming’s Articles of Association from the agenda of the AGM scheduled for Wednesday, 24 May 2017 at 14:00 hours.
Pharming Group Interim Report on Financial Results for the First Quarter 2017
Financial updatesPharming Group N.V. presents its (unaudited) financial report for the quarter ended 31 March 2017.
Pharming announces refinancing of its existing debt by a single US$100 million debt facility on improved commercial terms
Financial updatesPharming Group N.V. announces that it has completed a new US$100 million finance agreement with Orbimed Advisors.
Pharming Group Report on Preliminary Financial Results for 2016
Financial updatesPharming Group N.V. presents its (unaudited) financial report for the full year ended 31 December 2016.
Prospectus 2016
Financial updatesProspectus 2016 is available for download.
Pharming Launches Rights Issue to raise €12.1 million as part of RUCONEST® North American Rights Acquisition Financing
Financial updatesPharming Group N.V. announces the launch of a 1 for 7 Rights Issue of up to 58,943,624 shares to raise approximately €12.1 million to existing shareholders its financing plans to enable the completion of the acquisition of the North American commercialization rights to RUCONEST® from Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) (“Valeant”), as announced on 9 August 2016 (the “Transaction”).
Pharming Announces Financing Plans for Closing of RUCONEST® North American Rights Acquisition
Financial updatesPharming Group N.V. announces its financing plans to enable the completion of the acquisition of the North American commercialization rights to RUCONEST® from Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) (“Valeant”), as announced on 9 August 2016.